AstraZeneca Media - press releases, upcoming events, corporate reports and facts, image library

Our Senior Executive Team speaking at a leadership conference

Here you will find our corporate press releases, details on upcoming events and other useful information for business and financial media

Latest news collapse
- 02 September 2010 European Commission Issues Positive Decision for Approval of Seroquel XR as an Add-On Treatment of Major Depressive Disorder
  AstraZeneca today announced that the European Commission (EC) has issued a positive decision for the approval of once-daily SEROQUEL XR (quetiapine fumarate) Extended Release Tablets as an add-on treatment of major depressive episodes in patients with Major Depressive Disorder (MDD) who have had sub-optimal response to antidepressant monotherapy.
- 30 August 2010 MedImmune receives complete response letter on motavizumab
  AstraZeneca today announced that MedImmune, its biologics unit, has received a second complete response letter (CRL) on motavizumab from the US Food and Drug Administration (FDA).
more news
- previous
- - 1
  - 2
  - 3
  - 4
  - 5
- next
Financial results collapse

Second quarter and half year results 2010 announced Thursday, 29 July 2010.
View details of the event
View financial calendar

Photo & video library collapse

Here you can download pictures from our photo library
Broadcast footage of AstraZeneca products and activities is available from our Broadcast Centre (requires registration)
Key Facts collapse
- AstraZeneca is a global, innovation-driven, integrated biopharmaceutical company.
- We discover, develop, manufacture and market prescription medicines for six important areas of healthcare, which include some of the world’s most serious illnesses: cancer, cardiovascular, gastrointestinal, infection, neuroscience, and respiratory and inflammation. Read more about our medicines.
- We employ over 62,000 people (47% in Europe, 31% in the Americas and 22% in Asia, Africa and Australasia). Read more about our employees and our culture.
More facts about AstraZeneca
Research & Development expand